Skip to main content
. 2024 Mar 1;13:26. doi: 10.1186/s40164-024-00493-8

Table 11.

Adverse events in clinical trials of drug conjugates for lung cancer treatment

Drug name Type NCT number Time frame Number of AEs All-cause mortality Number of other AEs Description
Rova-T ADC NCT03543358 Up to 13.6 months Not specified 1 (33%) 1 (33%) Gastrointestinal disorders; psychiatric disorders
TIVDAK ADC NCT03245736 Day 1 to week 24 1 (20%) 0 (0%) 5 (100%) Nervous system disorders
TIVDAK ADC NCT02001623 1 to 249 days 6 (40%) 1 (7%) 15 (100%) Nausea

ADC antibody drug conjugate, AE adverse event